Study guide

20.3 Medicinal Chemistry Essentials

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

20.3 Medicinal Chemistry Essentials

Key Takeaways Explain This Topic AI

Structure-activity relationship (SAR) describes how chemical structure determines biological activity, and selective toxicity (Ehrlich) is the principle that a drug harms the pathogen without harming the host

Beta-lactam antibiotics (penicillins, cephalosporins, carbapenems, monobactams) share a beta-lactam ring, bind penicillin-binding proteins, and inhibit peptidoglycan cell-wall synthesis; their selectivity rests on the fact that human cells lack a cell wall

Penicillin core is 6-aminopenicillanic acid (thiazolidine plus beta-lactam ring); cephalosporin core is 7-aminocephalosporanic acid, with successive generations expanding Gram-negative coverage

Sulfonamides are PABA analogs that competitively inhibit dihydropteroate synthase (DHPS), and trimethoprim inhibits dihydrofolate reductase (DHFR), producing sequential folate-synthesis blockade (co-trimoxazole); humans are spared because they obtain folate from the diet

Tetracyclines bind the 30S ribosomal subunit and are contraindicated in pregnancy and children under 8 due to tooth and bone deposition; aminoglycosides (gentamicin) also bind 30S and cause nephrotoxicity and ototoxicity; statins inhibit HMG-CoA reductase with a pharmacophore that mimics mevalonate

Last updated: August 2026

Structure-Activity Relationship and Selective Toxicity

Structure-activity relationship (SAR) is the study of how a drug's chemical structure determines its biological activity — small changes in a molecule can dramatically alter potency, spectrum, metabolism, or toxicity. Selective toxicity , a concept articulated by Paul Ehrlich , is the principle that an ideal antimicrobial harms the pathogen without harming the host. Most antibiotic classes achieve selective toxicity by targeting structures or pathways present in microbes but absent in humans.

Beta-Lactam Antibiotics

The beta-lactam antibiotics — penicillins, cephalosporins, carbapenems, and monobactams — all share a four-membered beta-lactam ring . They bind penicillin-binding proteins (PBPs) and inhibit transpeptidation , the final cross-linking step of peptidoglycan (cell-wall) synthesis. Bacterial lysis follows because the cell wall is weakened.

The basis of selective toxicity is that human cells lack a peptidoglycan cell wall , so the target does not exist in the host.

Penicillin Core

The penicillin nucleus is 6-aminopenicillanic acid (6-APA) , consisting of a thiazolidine ring fused to the beta-lactam ring. Modifications of the side chain at C-6 change the drug's properties:

  • Side-chain change Example drug Result
  • Acid-stable side chain Penicillin V Survives gastric acid → oral use
  • Broad-spectrum aminopenicillin Amoxicillin / ampicillin Extended Gram-negative coverage

Anti-staphylococcal (resists penicillinase) Meticillin / flucloxacillin Stable against staphylococcal beta-lactamase

Extended-spectrum with beta-lactamase inhibitor Amoxicillin + clavulanate Restores activity against beta-lactamase producers

Cephalosporin Core

The cephalosporin nucleus is 7-aminocephalosporanic acid (7-ACA) , a beta-lactam ring fused to a dihydrothiazine ring. Successive generations progressively expand Gram-negative coverage while retaining or reducing Gram-positive activity:

  • 1st generation (cefalexin, cefazolin) — Gram-positive strong
  • 2nd generation (cefuroxime) — balanced
  • 3rd generation (ceftriaxone, cefotaxime, ceftazidime) — Gram-negative, CNS penetration
  • 4th generation (cefepime) — broad including Pseudomonas
  • 5th generation (ceftaroline) — MRSA coverage
  • Sulfonamides and Trimethoprim: Sequential Folate Blockade

Bacteria must synthesise folate de novo; humans obtain folate from the diet and cannot synthesise it. This difference is the basis of selective toxicity.

Sulfonamides (e.g. sulfamethoxazole ) are structural analogs of PABA (para-aminobenzoic acid). They competitively inhibit dihydropteroate synthase (DHPS) , the enzyme that condenses PABA with pteridine to form dihydropteroate — an early step in folate synthesis.

Trimethoprim inhibits dihydrofolate reductase (DHFR) , a later step that converts dihydrofolate to tetrahydrofolate.

Combining sulfamethoxazole with trimethoprim ( co-trimoxazole ) produces sequential blockade of two consecutive steps in the same pathway, yielding synergistic bactericidal activity.

Fluoroquinolones

Fluoroquinolones (e.g. ciprofloxacin, levofloxacin, moxifloxacin ) share the quinolone pharmacophore and target bacterial DNA gyrase (topoisomerase II in Gram-negatives) and topoisomerase IV (in Gram-positives), blocking DNA replication and repair. Mammalian topoisomerases are structurally different enough to spare host cells.

Protein-Synthesis Inhibitors

Ribosomes are a rich target for selective toxicity because bacteria have 70S ribosomes (30S + 50S subunits) while humans have 80S ribosomes (40S + 60S).

Class Example Ribosomal target Key safety issue

Macrolides Azithromycin, erythromycin, clarithromycin 50S subunit QT prolongation, CYP3A4 inhibition (erythro/clarithro)

Tetracyclines Doxycycline, tetracycline 30S subunit Tooth discolouration and bone effects — contraindicated in pregnancy and children <8 years

Aminoglycosides Gentamicin, tobramycin, amikacin 30S subunit Nephrotoxicity and ototoxicity — monitor levels and renal function

  • Chloramphenicol Chloramphenicol 50S subunit Bone marrow suppression, grey baby syndrome
  • Lincosamides Clindamycin 50S subunit C. difficile colitis
  • Statins: HMG-CoA Reductase Inhibitors

Statins (e.g. atorvastatin, simvastatin, rosuvastatin) inhibit HMG-CoA reductase , the rate-limiting enzyme of cholesterol synthesis that converts HMG-CoA to mevalonate . The statin pharmacophore is structurally analogous to the transition state of mevalonate, allowing competitive inhibition at the active site. This is a classic example of rational medicinal chemistry: the drug is a mevalonate mimic .

Resistance Mechanisms

Understanding resistance helps the exam because it links structure to clinical failure. Beta-lactam resistance most commonly arises through beta-lactamase enzymes that hydrolyse the beta-lactam ring. MRSA carries the mecA gene encoding a low-affinity PBP2a, so meticillin and most beta-lactams cannot bind effectively. Carbapenemases (e.g. KPC, NDM-1) confer broad resistance including to carbapenems. Beta-lactamase inhibitors such as clavulanate, tazobactam, and avibactam restore activity by suicidally inhibiting the enzyme, which is why amoxicillin-clavulanate and piperacillin-tazobactam are common exam pairings.

Fluoroquinolone resistance arises through target mutations in DNA gyrase (gyrA) and topoisomerase IV (parC) and through efflux pumps. Macrolide resistance commonly arises via erm -mediated methylation of the 23S rRNA target * (MLS_B cross-resistance) or mef -mediated efflux *.

Pharmacophore Concept

A pharmacophore is the three-dimensional arrangement of steric and electronic features a molecule needs to bind a specific biological target and elicit a response. Recognising a shared pharmacophore helps predict class effects and cross-allergy. Examples on the blueprint:

Beta-lactam pharmacophore (four-membered lactam ring) — shared by penicillins, cephalosporins, carbapenems, monobactams → shared allergy risk

  • Quinolone pharmacophore (4-quinolone core with a fluorine at C-6 in fluoroquinolones) → class cross-resistance
  • Statin pharmacophore (mevalonate transition-state mimic) → HMG-CoA reductase inhibition
  • Sulfonamide pharmacophore (PABA mimic) → folate-synthesis inhibition
  • Exam Pearls

Selective toxicity arises from absent host targets (cell wall, 70S ribosome, DNA gyrase, DHPS) or differences in affinity (fungal ergosterol vs mammalian cholesterol).

Co-trimoxazole is the canonical example of sequential blockade .

Tetracyclines and aminoglycosides both bind 30S but cause very different toxicities — do not confuse them.

Cross-allergy within the beta-lactam class depends on the side chain; penicillins and cephalosporins share partial cross-reactivity (about 1-10%), monobactams (aztreonam) largely do not, and carbapenems have low cross-reactivity.

When asked why a drug is safe for humans, the answer is almost always that the target is absent in humans (cell wall, DHPS, DNA gyrase, 70S ribosome) or different in affinity (HMG-CoA reductase, fungal ergosterol).